These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9567055)

  • 1. A method to compare two samples of recurrence data.
    Doganaksoy N; Nelson W
    Lifetime Data Anal; 1998; 4(1):51-63. PubMed ID: 9567055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An additive-multiplicative rates model for recurrent event data with informative terminal event.
    Sun L; Kang F
    Lifetime Data Anal; 2013 Jan; 19(1):117-37. PubMed ID: 22965680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A flexible semiparametric transformation model for recurrent event data.
    Dong L; Sun L
    Lifetime Data Anal; 2015 Jan; 21(1):20-41. PubMed ID: 24241908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerated intensity frailty model for recurrent events data.
    Liu B; Lu W; Zhang J
    Biometrics; 2014 Sep; 70(3):579-87. PubMed ID: 24588756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: Recurrence of superficial bladder carcinoma after intravesical instillation of Mitomycin-C.
    Parmar MK
    Br J Urol; 1989 Dec; 64(6):659. PubMed ID: 2516758
    [No Abstract]   [Full Text] [Related]  

  • 6. Chemotherapy for bladder cancer.
    Sonpavde G; Rawat A; Naveed F
    N Engl J Med; 2003 Dec; 349(23):2272-3; author reply 2272-3. PubMed ID: 14663870
    [No Abstract]   [Full Text] [Related]  

  • 7. Local recurrence after radical cystectomy for invasive bladder cancer: an analysis of predictive factors.
    Honma I; Masumori N; Sato E; Takayanagi A; Takahashi A; Itoh N; Tamagawa M; Sato MA; Tsukamoto T
    Urology; 2004 Oct; 64(4):744-8. PubMed ID: 15491713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Oral tegafur plus mitomycin versus intravesical mitomycin alone in the prevention of recurrence in stage Ta bladder tumors].
    Server Pastor G; Rigabert Montiel M; Bañón Pérez V; Valdelvira Nadal P; Cao Avellaneda E; García Hernández JA; Pérez Albacete M
    Actas Urol Esp; 2003 Jun; 27(6):438-41. PubMed ID: 12918150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A penalized algorithm for event-specific rate models for recurrent events.
    Bouaziz O; Guilloux A
    Biostatistics; 2015 Apr; 16(2):281-94. PubMed ID: 25388299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prevention and treatment of bladder tumors recurrence with furtulon].
    Wang H; Li H; Zang M; Xu F
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2000 Feb; 22(1):79-81. PubMed ID: 12903500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smoothing spline ANOVA frailty model for recurrent event data.
    Du P; Jiang Y; Wang Y
    Biometrics; 2011 Dec; 67(4):1330-9. PubMed ID: 21457192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of European Organization for Research and Treatment of Cancer (EORTC) risk tables for the prediction of recurrence and progression of non-muscle invasive bladder cancer after intravesical pirarubicin instillation].
    Xu C; Jiang XZ; Zhang NZ; Ma L; Xu ZS
    Zhonghua Zhong Liu Za Zhi; 2012 Aug; 34(8):609-12. PubMed ID: 23158996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors for survival and bladder recurrence in transitional cell carcinoma of the upper urinary tract.
    Morioka M; Jo Y; Furukawa Y; Kinugawa K; Sone A; Matsuki T; Kobayashi T; Fujii T; Tanaka H
    Int J Urol; 2001 Jul; 8(7):366-73. PubMed ID: 11442658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective chemoprophylaxis guided by multifactorial analysis in superficial bladder cancer.
    Vera-Donoso CD; Llopis B; Oliver F; Gallego J; Ruiz J; Vidal J; Jiménez Cruz JF
    Eur Urol; 1990; 17(3):219-22. PubMed ID: 2112473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intravesical therapy: Influence on superficial bladder cancer recurrence].
    García Rodríguez J; Fernández Gómez JM; Escaf Barmadah S; González Alvarez RC; Jalón Monzón A; Martínez Gómez FJ; Sánchez Trilla A; Regadera Sejas J
    Arch Esp Urol; 2007; 60(1):36-43. PubMed ID: 17408170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Value of European Organisation for Research and Treatment of Cancer score system for predication of immediate postoperative intravesical instillation of pirarubicin after transurethral resection of non-muscle invasive bladder cancer].
    Ding XL; Yang DL; Yan RP; Li ZP; Ye CW; He J; Yu L; He SC; Li HD
    Zhonghua Zhong Liu Za Zhi; 2018 Apr; 40(4):308-312. PubMed ID: 29730921
    [No Abstract]   [Full Text] [Related]  

  • 17. Joint analysis of panel count data with an informative observation process and a dependent terminal event.
    Zhou J; Zhang H; Sun L; Sun J
    Lifetime Data Anal; 2017 Oct; 23(4):560-584. PubMed ID: 27449506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [EORTC risk tables--a new diagnostic tool in urology].
    Bobiński J; Lipiński M
    Pol Merkur Lekarski; 2009 Dec; 27(162):524-8. PubMed ID: 20120722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer.
    Arends TJ; van der Heijden AG; Witjes JA
    J Urol; 2014 Sep; 192(3):708-13. PubMed ID: 24704017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prevention of the recurrence of bladder tumors with local adriamycin therapy].
    Somogyi L; Török A; Bors G; Frang D
    Orv Hetil; 1984 Oct; 125(41):2503-6. PubMed ID: 6493764
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.